Jazz Pharmaceuticals Public Limited Company (JAZZ)

Over the past year, Jazz Pharmaceuticals' stock has seen a significant change, with a 37.16% increase from February 3, 2025, to February 2, 2026, and a 52-week trading range between $95.49 and $182.99. S&P Global Ratings upgraded Jazz Pharmaceuticals to 'BB' due to strong operating performance. Xywav and Epidiolex experienced 15% year-over-year sales increases through the first three quarters of 2024. Recent court decisions related to Jazz's sleep franchise have improved expectations for sustainable revenue increases. Total revenues increased by 7% in Q3 2025 compared to the same period in 2024. Jazz Pharmaceuticals reported results from its HERIZON-GEA trial and plans to submit a supplemental Biologics License Application in the first half of 2026. Analysts have a "Moderate Buy" consensus rating for JAZZ, with an average price target of $205.67.

Specific information regarding the demand seasonality for Jazz Pharmaceuticals Plc's products and services was not explicitly detailed. However, the company's neuroscience segment is projected to have a CAGR of 7% from 2020 to 2026, and the oncology segment is forecasted to expand at a significantly higher CAGR of 16%, indicating consistent demand and growth across its key therapeutic areas. The company's ability to record its highest quarterly sales ever in September 2024 also suggests robust, ongoing demand for its products.

Jazz Pharmaceuticals Plc is a specialty biopharmaceutical company focused on identifying, developing, and commercializing medicines for serious diseases with limited treatment options. The company operates in the biotechnology and pharmaceutical sectors, focusing on therapeutic areas such as narcolepsy, cancer, pain, and psychiatry. Its major marketed products include Xyrem, Sunosi, Erwinaze, Defitelio, Vyxeos, Epidiolex/Epidyolex, Xywav, Zepzelca and Rylaze.

Jazz Pharmaceuticals Plc is headquartered in Dublin, Ireland, with a significant presence in Palo Alto, CA, Philadelphia, PA, and England. The company has a commercial and operational footprint across Europe, North America, and Australia, and is expanding into Japan. They collaborate with other companies to distribute their medicines globally, including in Asia Pacific and Latin America. Manufacturing facilities are located in the U.S., U.K., Ireland, and Italy.

In 2024, Jazz Pharmaceuticals emphasized its commitment to patient-centric innovation and corporate sustainability. The company made significant progress in delivering life-changing medicines, including securing FDA approval for a treatment for adults with Biliary Tract Cancer (BTC). They have also focused on integrating patient insights into clinical trial design and improving patient-facing materials. The company's corporate sustainability and social impact strategy focuses on patients, people, community, and the planet, with efforts in philanthropy, volunteerism, and enhancing environmental sustainability processes.

Institutional investors hold approximately 54.96% of Jazz Pharmaceuticals' stock, while insiders own 3.57%, and public companies and individual investors account for 41.47%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Dimensional Fund Advisors Lp, Capital World Investors, LSV Asset Management, iShares, State Street Corp, Jpmorgan Chase & Co, and American Funds Fundamental Investors.